WBMP-4 / Welt Bio-Molecular Pharma - LARVOL DELTA

Monoclonal antibodies targeting the B-cell receptor complex directly induce widespread kinase inhibition and B-cell killing for the treatment of leukemia and lymphoma (AACR 2026) - "WBMP has previously described WBMP-4, a pro-apoptotic anti-membrane IgM antibody...Cell growth, MTT, and additional kinome assays will define the cytotoxicity characteristics of mAbs at varying doses and compared to existing B-cell therapeutics (i.e. ibrutinib, acalabrutinib, venetoclax, rituximab).WBMP has successfully applied a drug discovery system to develop a pipeline of B-cell cancer therapeutics...Those mAbs which are determined to be safe and effective will be considered for further clinical development. Together, this pipeline of novel mAbs covers the spectrum of B-cell malignancies, and the availability of multiple, distinct, directly effective mAbs against B-cells offers the potential for combination treatment strategies that can be optimized for specific tumor-types."

Hematological Malignancies • Leukemia • Lymphoma • Oncology

Membrane protein expression and activity following inhibition of B-cell receptor-initiated signaling by WBMP-4, a therapeutic antibody for leukemia/lymphoma (AACR 2024) - "This work will be considered in the context of our ongoing research on WBMP-4's inhibition of intracellular signaling pathways, and the resulting biologic effects, and will contribute to the continued development of WBMP-4 by providing an understanding of the effects achieved (cell growth inhibition, cell differentiation, apoptosis) at different dosages and if these effects are maintained over time. As a novel, efficacious, and low toxicity treatment strategy for B-cell leukemia and lymphoma, WBMP-4 has significant clinical potential."

IO biomarker • Burkitt Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Oncology • BCL2 • CD20 • CD21 • CD22 • CD79A • CD79B • CD81 • CXCR4 • EBF1 • FCGR2A • MYC • PAX5 • STAT5

A novel drug discovery platform identifies epitopes on driver receptors that can be targeted to induce widespread kinase inhibition and cancer cell death (AACR 2025) - "WBMP-4's global kinase inhibition encompasses the effects of approved kinase inhibitor drugs (i.e. BTK, PI3K, and Bcl-2 inhibitors), and is designed to be more tumor-restrictive; WBMP-4 only affects IgM-expressing B-cells, sparing healthy B-cells that express other classes of Ig (i.e. IgG, IgA, IgD, or IgE). This tumor specificity and potent inhibitory effects make WBMP-4 a promising clinical candidate."

IO biomarker • Hematological Malignancies • Lymphoma • Oncology • CD79B • ZAP70

The development of directly active monoclonal antibodies: monotherapies with combined antibody-dependent cellular cytotoxic and tyrosine kinase inhibitory effects (SITC 2025) - "WBMP-4's global kinase inhibition encompasses the effects of approved inhibitor drugs (i.e. BTK, PI3K, and Bcl-2 inhibitors), and should be more tumor-restrictive; WBMP-4 only affects IgM-expressing B-cells, sparing healthy B-cells that express other classes of Ig. This tumor specificity and potent inhibitory effects make WBMP-4 a promising clinical candidate."

IO biomarker • Hematological Malignancies • Lymphoma • Oncology • CD79B • ZAP70

Anti-membrane IgM monoclonal antibody, WBMP-4, induces apoptosis in B-cell malignancies by modulation of kinase expression and phosphorylation (AACR 2023) - "These data support the concept that WBMP-4 binds an epitope on mIgM that is critical to its signal transduction to CD79a/b.Due to WBMP-4’s specific targeting of IgM-expressing B-cells, we expect that the toxicities associated with approved therapies upon their interaction with non-lymphatic tissue (e.g. bleeding, infection, cytopenia, arrhythmia, secondary malignancies) will be avoided. With potent anti-tumor activity and expected reduced toxicities, WBMP-4 is a compelling candidate for clinical development."

Burkitt Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Oncology • CD79A • CD79B • ZAP70